US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Photocure ASA: Results for the third quarter of 2024

Oslo, Norway, 13 November 2024 - Photocure ASA (OSE:PHO) today reported Hexvix[®]/Cysview[®] revenues of NOK 120.1 million in the third quarter of 2024 (Q3 2023: NOK 107.3 million), and  EBITDA of NOK 5.0 million (NOK 3.3 million) for the Company. Photocure reiterates its 2024 financial guidance and continues to expect consolidated product revenue growth of 6% to 9% in constant currency and positive EBITDA excluding business development expenses.“We delivered solid performance in the third quarter, generating 12% Hexvix/Cysview revenue growth and NOK 5.0 million in EBITDA. Year-to-date, we

Photocure ASA: Invitation to presentation of third quarter 2024 financial results

Oslo, Norway, 6 November 2024: Photocure ASA (Photocure, PHO: OSE) will announce the third quarter 2024 financial results on Wednesday 13 November 2024 at 08:00 CET and will present a live webcast at 14:00 CET the same day.The quarterly report and presentation will be published at 08:00 CET and will be publicly available at www.photocure.com. The investor presentation will be streamed live and be hosted by Dan Schneider, CEO and Erik Dahl, CFO. The presentation will be held in English and questions can be submitted throughout the event. The presentation is scheduled to conclude at 14:45

Photocure Partner Asieris announces Marketing Approval by the National Medical Products Administration for Hexvix in China

Oslo, Norway, November 5, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has communicated today that its parent company Jiangsu Yahong Meditech Co., Ltd has received the marketing authorization for Hexvix[®] in China:The announcement states: Jiangsu Yahong Meditech Co., Ltd (hereinafter referred to as the "Company") has received the "Drug Registration Certificate" issued by the National Medical Products Administration, approving the marketing of the company's APL-1706 (Hexaminolevulinate Hydrochloride For

Photocure Partner Asieris Unveils Cevira (APL-1702) Phase III Subgroup Analysis by Age Groups at the 2024 CSCO Annual Meeting

Press Release – Oslo, Norway, September 30, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated that international multicenter Phase III clinical study data for its non-surgical treatment candidate Cevira[®] (APL-1702) for cervical High-Grade Squamous Intraepithelial Lesion (HSIL) has been published by the 27[th] Chinese Society of Clinical Oncology (CSCO) Annual Meeting as a poster, focusing on the analysis of different age subgroups regarding the six-month pathological regression rate and HPV clearance

Photocure establishes Named Patient Program to provide access to Hexvix in South Africa

Press Release – Oslo, Norway, September 27, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that it entered into an agreement with Equity Pharmaceuticals PTY Limited, part of the Clinigen group, in September, to initiate a Named Patient Program (NPP) enabling bladder cancer patients in South Africa to receive blue light cystoscopy (BLC[®]) with Hexvix[®].Named Patient Programs (NPPs) provide access to medicines in response to requests by physicians on behalf of specific, or “named,” patients when those medicines are not licensed or available in the patients’ home

Cevira (APL-1702): Photocure Partner Asieris Unveils Efficacy Data of Non-Surgical Treatment of Cervical HSIL at the 2024 PDT&PD Conference

Press Release – Oslo, Norway, September 17, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has communicated today that international multicenter Phase III clinical trial data for its non-surgical treatment for cervical HSIL (High-Grade Squamous Intraepithelial Lesion) product candidate Cevira[® ](APL-1702) have been accepted for oral presentation by the International Photodynamic Therapy & Photodiagnosis Update Conference in Germany on September 17, 2024, focusing on the efficacy data related to the regression of

Photocure ASA: Results for the second quarter of 2024

Oslo, Norway, 7 August 2024 - Photocure ASA (OSE:PHO), The Bladder Cancer Company, today reported Hexvix®/Cysview® revenues of NOK 122.4 million in the second quarter of 2024 (Q2 2023: NOK 115.9 million) and EBITDA of NOK 27.8 million (NOK 23.4 million). Photocure reiterates its 2024 financial guidance of product revenue growth of 6% to 9% in constant currency and positive EBITDA excluding business development expenses. Photocure now expects new and upgraded Saphira™ installations in the U.S. in the range of 55 to 70 towers for the full year, up from the previous range of 40 to 70 towers.“

Photocure ASA: Invitation to presentation of second quarter and first half year 2024 financial results

Oslo, Norway, 31 July 2024: Photocure ASA (Photocure, PHO: OSE) will announce the second quarter and first half year 2024 financial results on Wednesday 7 August 2024 at 08:00 CEST and will present a live webcast at 14:00 CEST the same day.The quarterly report and presentation will be published at 08:00 CEST and will be publicly available at www.photocure.com. The investor presentation will be streamed live and be hosted by Dan Schneider, CEO and Erik Dahl, CFO. The presentation will be held in English and questions can be submitted throughout the event. The presentation is scheduled to

Photocure and Richard Wolf Enter into Agreement to Develop a High-Definition Flexible Blue Light Cystoscope for Global Commercialization

Oslo, Norway, July 15, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announces that it has entered into a strategic agreement with Richard Wolf GmbH to develop and commercialize a next-generation 4K LED high-definition (HD) reusable flexible blue light cystoscope based on Richard Wolf’s System blue technology. The partnership between Photocure and Richard Wolf is focused on developing technologically advanced flexible blue light cystoscopy (BLC[®]) equipment for the global market so that physicians who treat patients with bladder cancer can offer the benefits of BLC with

Photocure Announces Mobile BLC Tower Initiative to Expand Access to Cysview in the U.S.

Press Release – Oslo, Norway, June 4, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announces that it has commenced activities to support a new initiative enabling U.S. Hospitals and Clinics to offer blue light cystoscopy (BLC[®]) using a mobile capital equipment model. The initiative is aligned with a recently executed agreement between Karl Storz and ForTec Medical, aimed at providing on-demand Saphira™ BLC equipment to hospitals in the U.S. leveraging ForTec’s utilization-driven mobile equipment business model.The mobile tower opportunity is intended to increase

Photocure ASA – Annual general meeting held

Oslo, Norway, 23 May 2024: Photocure ASA (OSE: PHO), held its annual general meeting on 23 May 2024 at 17:00 hours (CEST).The minutes from the general meeting setting out the resolutions are attached hereto. For further information, please contact: Photocure CFO Erik DahlTel: + 47 450 55 000Email: ed@photocure.no About Photocure ASA Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, which makes cancer cells glow bright pink, has led to better health outcomes for patients worldwide.

Photocure ASA: Results for the first quarter of 2024

Oslo, Norway, 15 May 2024 - Photocure ASA (OSE:PHO) today reported Hexvix[®]/Cysview[®] revenues of NOK 116.8 million in the first quarter of 2024 (Q1 2023: NOK 105.9 million), and EBITDA of NOK 7.9 million (NOK -1.2 million) following positive operational developments and cost control. The Company reiterates its business and financial guidance for 2024 with 40 to 70 new and upgraded Saphira™ blue light tower installations during the year, product revenue growth of 6% to 9% in constant currency, and positive EBITDA excluding business development expenses.“Photocure delivered positive

Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Cevira in China

Press Release – Oslo, Norway, May 12, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that the National Medical Products Administration (NMPA) has accepted its new drug application (NDA) for the regulatory review of Cevira[®] (APL-1702, Hexaminolevulinate Hydrochloride Ointment Photodynamic Therapy System) for potential marketing authorization in China. Cevira (APL-1702) is a photodynamic drug-device combination product in development for the non-surgical treatment of high-grade squamous

Photocure ASA: Invitation to presentation of first quarter 2024 financial results

Oslo, Norway, 8 May 2024: Photocure ASA (Photocure, PHO: OSE) will announce the first quarter 2024 financial results on Wednesday 15 May 2024 at 08:00 CEST and will present a live webcast at 14:00 CEST the same dayThe quarterly report and presentation will be published at 08:00 CEST and will be publicly available at www.photocure.com. The investor presentation will be streamed live and be hosted by Dan Schneider, CEO and Erik Dahl, CFO. The presentation will be held in English and questions can be submitted throughout the event. The presentation is scheduled to conclude at 14:45 CEST.

Bladder Cancer: Long-Term Benefits of Blue Light Cystoscopy and Enhanced Detection with HD Technology Unveiled at AUA 2024

Press Release – Oslo, Norway, May 7, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces its participation in the congress, and two abstract presentations at the AUA 2024: the American Urological Association Annual Congress 2024 was held May 3-6, 2024, in San Antonio, TX, USA. The results of the BRAVO study performed within the VA healthcare system showed significant decreases in the risk of recurrence and progression, as well as the potential for improved overall survival in patients who received a blue light cystoscopy (BLC[®]) compared to patients whose cystoscopy was

Photocure ASA – Notice of the Annual General Meeting 23 May 2024

Oslo, Norway, 30 April 2024: Photocure ASA (OSE: PHO), calls for the annual general meeting of Photocure ASA to be held on 23 May 2024 at 17:00 hours (CEST), virtual through the general meeting portal administered by Euronext Securities Oslo (the "Euronext Securities Portal").The general meeting will be webcasted live and a link will be available on the company's website in due time in advance of the general meeting. It will not be possible to attend in person. Shareholders may also vote in advance or submit a proxy with voting instructions. The notice convening the general meeting,

Photocure ASA: Annual Report 2023

Oslo, Norway, 30 April 2024: Photocure ASA today announces the publication of the Annual Report and integrated ESG report for 2023.The Board of Directors of Photocure ASA has approved the annual accounts for 2023. The financial statements and annual report for the financial year 2023 are together with the ESG report and auditor's report attached to this notice. The ESEF file for 2023 is also attached. The documents are enclosed and also made available at the company's website under https://photocure.com/investors-hub/investors-events-and-presentations. For further information, please

Bladder Cancer: pivotal trial results and new real-world evidence, to be presented at AUA 2024, demonstrate improved diagnostic and clinical outcomes with blue light cystoscopy

Press Release – Oslo, Norway, April 30, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces its participation in the American Urological Association Annual Congress (AUA 2024) to be held May 3-6, 2024 in San Antonio, TX, USA.Two AUA program highlights will feature Blue Light Cystoscopy with Cysview[®] study data: · On Sunday, May 5[th], Dr. Sanjay Das will present the study, “Use of Blue Light Cystoscopy Among Non-Muscle Invasive Bladder Cancer Patients and Outcomes in an Equal Access setting: A Propensity Scored Matched Analysis”The study, known as BRAVO (Bladder

Photocure ASA – Share option grant

Oslo, Norway, 25 April 2024 – Photocure ASA (the "Company") (OSE: PHO) refers to its previous stock exchange announcement on 21 December 2023 regarding the cancellation of up to 1,400,428 options and re-issue of options to employees. The Company today announces the status for the cancellation and re-issue of options. In addition, options have been issued to Ryan Kitchen that has joined the Company as Head of Corporate Strategy, and a customary annual issue of options to the board as resolved by the 2023 general meeting has been made. As of today, a total of 1,400,428 options have been

European Association of Urology (EAU) 2024 congress features new data on modern technology use in bladder cancer care

Press Release – Oslo, Norway, April 8, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces its participation in the congress, and two abstract presentations at the 2024 European Association of Urology congress (EAU) in Paris, France, highlighting the benefits of Blue Light Cystoscopy (BLC[®]) in Bladder Cancer management.The EAU annual meeting is one of the largest international meetings in the urology calendar, showcasing the latest and most relevant clinical and scientific advancements in this area of patient care. This year’s event was held on April 5-8, 2024, and

Photocure to Participate in the 23[rd] Annual Needham Virtual Healthcare Conference

OSLO, Norway, April 5, 2024 – Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces that President and Chief Executive Officer, Dan Schneider will present a corporate overview and host 1-on-1 meetings with investors at the 23[rd] Annual Needham Healthcare Conference being held virtually April 8-11, 2024.Presentation Details: Date: April 11, 2024 Time: 10:15am ET (4:15pm CET) Webcast Link: https://wsw.com/webcast/needham117/pho.ol/2531984About the Needham Healthcare Conference The 23[rd] Annual Needham Virtual Healthcare Conference will feature leading public and

New Publication: Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy

Press release – Oslo, Norway, March 28, 2024: Photocure ASA, The Bladder Cancer Company, announces the publication of the study “Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter Registry” in the journal Cancers this week. This study aims to evaluate heterogeneity in characteristics of blue light cystoscopy (BLC[®]) for detection of malignant lesions among various races with non‐muscle invasive bladder cancer (NMIBC).The study author Sia Daneshmand, MD and the participants of the BLC with Cysview Study Group collected

Photocure Partner Asieris announces positive international Phase III clinical trial results for Cevira and data presentations at the 2024 EUROGIN Congress and SGO Annual Meeting

Press Release – Oslo, Norway, March 18, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has communicated today the Phase III clinical study results for its non-surgical treatment candidate for cervical high-grade squamous intraepithelial lesions (HSIL) Cevira[®] (APL-1702). The results were presented at two recent medical congresses and demonstrated highly statistically significant efficacy and a favorable safety profile for Cevira, with a significant clearance rate of high-risk HPV16 and/or HPV18 compared to placebo

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media